-
Navitoclax is an orally active Bcl-2 inhibitor targeting to Bcl-xL, Bcl-2, Bcl-w, with anti-tumor activity in vitro and in vivo.
-
Talacotuzumab is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure.
-
Rohinitib is a potent and specific eIF4A inhibitor that induce apoptosis of AML cell lines and shows anti-AML effects in vivo.
-
Olutasidenib (FT-2102) is an orally active, brain penetrant inhibitor of mutant IDH1. Olutasidenib is used for AML or MDS Research.
-
JS25 is a selective and covalent BTK inhibitor in hematological cancer. JS25 has blood brain barrier crossing property.
-
Purinostat mesylate is a potent and selective inhibitor of HDAC. Purinostat mesylate can be used for the research of lymphoblastic leukemia.
-
TK4g is a potent JAK inhibitor and can be used for studies of lymphatic-related diseases and leukemic cancers.
-
Pulrodemstat is a potent, selective, reversible and orally active LSD1 inhibitor, with anticancer effects.
-
Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin can be used for leukemia research.
-
5-Azacytidine is a DNMT inhibitor. 5-Azacytidine can be used for the research of myelodysplastic syndrome.
Categories
Diseases
Others
Archives
- March 2023 (1)
- February 2023 (1)
- December 2022 (2)
- November 2022 (1)
- October 2022 (1)
- September 2022 (1)
- July 2022 (1)
- June 2022 (1)
- May 2022 (1)
- February 2022 (1)
- January 2022 (1)
- December 2021 (1)
- October 2021 (3)
- August 2021 (2)
- June 2021 (1)
- May 2021 (1)
- April 2021 (1)
- March 2021 (1)
- February 2021 (1)
- August 2020 (1)
- July 2020 (2)
- June 2020 (2)
- May 2020 (1)
- March 2020 (1)
- January 2020 (2)
- December 2019 (1)
- November 2019 (1)
- September 2019 (3)
- August 2019 (3)
- July 2019 (1)
- June 2019 (1)
- May 2019 (1)
- April 2019 (1)
- March 2019 (1)